TY - JOUR
T1 - Strategies to promote implementation of core outcomes for medication adherence trials in rheumatology
T2 - A report from the OMERACT-Adherence Group
AU - Kordkheili, Aria Mohammadi
AU - Bekker, Charlotte
AU - Hoens, Alison M
AU - Voshaar, Marieke
AU - Campbell, Willemina
AU - Carmona, Loreto
AU - de Wit, Maarten
AU - March, Lyn
AU - Nielsen, Sabrina Mai
AU - Shea, Beverley J
AU - Toupin-April, Karine
AU - Tugwell, Peter
AU - Tymms, Kathleen
AU - Kelly, Ayano
AU - Adherence Working Group
N1 - Copyright © 2024. Published by Elsevier Inc.
PY - 2024/6
Y1 - 2024/6
N2 - OBJECTIVES: To identify barriers, facilitators, and strategies for future implementation of the OMERACT-Adherence Core Outcome Set (COS) in medication adherence trials for rheumatic conditions.METHODS: Preliminary Delphi survey findings were discussed at OMERACT 2023, utilising the Consolidated Framework for Implementation Research 2 to identify implementation barriers, facilitators, and solutions.RESULTS: Implementation strategies included simplifying the COS definitions, making it adaptabile for clinical practice and drug trials, adherence trial training workshops, and collaborating with key stakeholders such as payers and other COS developers.CONCLUSION: Ongoing collaboration with individuals and organisations within and beyond rheumatology ensures broader applicability of OMERACT-Adherence COS.
AB - OBJECTIVES: To identify barriers, facilitators, and strategies for future implementation of the OMERACT-Adherence Core Outcome Set (COS) in medication adherence trials for rheumatic conditions.METHODS: Preliminary Delphi survey findings were discussed at OMERACT 2023, utilising the Consolidated Framework for Implementation Research 2 to identify implementation barriers, facilitators, and solutions.RESULTS: Implementation strategies included simplifying the COS definitions, making it adaptabile for clinical practice and drug trials, adherence trial training workshops, and collaborating with key stakeholders such as payers and other COS developers.CONCLUSION: Ongoing collaboration with individuals and organisations within and beyond rheumatology ensures broader applicability of OMERACT-Adherence COS.
KW - Humans
KW - Medication Adherence
KW - Rheumatology
KW - Rheumatic Diseases/drug therapy
KW - Antirheumatic Agents/therapeutic use
KW - Delphi Technique
KW - Clinical Trials as Topic
KW - Outcome Assessment, Health Care
KW - Medication adherence
KW - OMERACT
KW - Implementation
UR - http://www.scopus.com/inward/record.url?scp=85189089030&partnerID=8YFLogxK
U2 - 10.1016/j.semarthrit.2024.152411
DO - 10.1016/j.semarthrit.2024.152411
M3 - Journal article
C2 - 38537323
SN - 0049-0172
VL - 66
JO - Seminars in Arthritis and Rheumatism
JF - Seminars in Arthritis and Rheumatism
M1 - 152411
ER -